RecruitingNCT06798740

Post Market Registry Study of Intracranial Aneurysms Treated With Sugita Clipping Devices


Sponsor

Mizuho Corporation

Enrollment

150 participants

Start Date

Apr 14, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of this study is to verify the performance and safety of the Sugita Aneurysm Clips devices when used as intended and to identify possible risk factors. Data collected will be used to support the continuing performance and safety of the devices in the post-market use environment in Europe. Subjects who have an intracranial aneurysm that the physician intends to treat with the subject devices will be included in the study. Subjects will be followup as per hospital standard of care for 5 years.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Subject has an intracranial aneurysm (ruptured or unruptured) that can be treated with one of the proposed devices.
  • Subject is adult, ≥18 years.
  • As per national regulations, subject or subject's legally authorized representative (LAR) has signed written informed consent.
  • Subject is willing to comply with scheduled visits and examinations per institutional standard of care.

Exclusion Criteria4

  • Subject is currently enrolled in or plans to be enrolled in a concurrent drug or device randomized study.
  • Subject has a condition which will not allow him/her to comply with his/her post-procedure follow up per the institutional standard of care (medical condition, subject living abroad and unable to return for follow- up, e.g.).
  • Subject does not meet IFU criteria of the subject device.
  • Subject is a child, <18 years.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESugita Titanium Aneurysm Clip II

Aneurysm clipping is a surgical procedure used to treat brain aneurysms.


Locations(1)

Universitätsklinikum Essen

Essen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06798740


Related Trials